Clorox (NYSE:CLX) Issues FY 2024 Earnings Guidance

Clorox (NYSE:CLX - Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.800-5.950 for the period, compared to the consensus estimate of 5.580. The company issued revenue guidance of -. Clorox also updated its FY24 guidance to $5.80-5.95 EPS.

Analyst Upgrades and Downgrades

CLX has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of Clorox from $145.00 to $152.00 and gave the stock a neutral rating in a research note on Thursday, January 18th. UBS Group lifted their price objective on shares of Clorox from $145.00 to $170.00 and gave the stock a neutral rating in a research report on Friday, February 2nd. DA Davidson restated a neutral rating and issued a $162.00 target price on shares of Clorox in a research note on Wednesday, April 17th. Jefferies Financial Group raised Clorox from an underperform rating to a hold rating and set a $145.00 price target on the stock in a research report on Tuesday, March 26th. Finally, Barclays lowered their price objective on Clorox from $148.00 to $136.00 and set an underweight rating for the company in a research report on Wednesday, April 10th. Four equities research analysts have rated the stock with a sell rating and thirteen have given a hold rating to the company. According to MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $148.63.

Clorox Stock Performance

Clorox stock traded down $1.11 during mid-day trading on Tuesday, hitting $147.81. The company had a trading volume of 1,784,278 shares, compared to its average volume of 1,217,056. The company has a current ratio of 0.89, a quick ratio of 0.57 and a debt-to-equity ratio of 11.37. The company has a market capitalization of $18.34 billion, a price-to-earnings ratio of 236.38, a P/E/G ratio of 2.32 and a beta of 0.43. The company's fifty day moving average is $149.35 and its 200-day moving average is $142.95. Clorox has a 12-month low of $114.68 and a 12-month high of $178.21.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings data on Thursday, February 1st. The company reported $2.16 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $1.08. Clorox had a net margin of 1.09% and a return on equity of 319.41%. The company had revenue of $1.99 billion during the quarter, compared to analysts' expectations of $1.80 billion. During the same quarter in the previous year, the company earned $0.98 earnings per share. The firm's revenue for the quarter was up 16.0% on a year-over-year basis. Equities research analysts predict that Clorox will post 5.52 EPS for the current year.

Clorox Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Wednesday, April 24th will be paid a dividend of $1.20 per share. This represents a $4.80 annualized dividend and a dividend yield of 3.25%. The ex-dividend date of this dividend is Tuesday, April 23rd. Clorox's payout ratio is 761.92%.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.